摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[2-[2-[[6-[[[2-[2-(Carboxymethoxy)ethoxy]acetyl]amino]methyl]-1,2,4,5-tetrazin-3-yl]methylamino]-2-oxoethoxy]ethoxy]acetic acid

中文名称
——
中文别名
——
英文名称
2-[2-[2-[[6-[[[2-[2-(Carboxymethoxy)ethoxy]acetyl]amino]methyl]-1,2,4,5-tetrazin-3-yl]methylamino]-2-oxoethoxy]ethoxy]acetic acid
英文别名
2-[2-[2-[[6-[[[2-[2-(carboxymethoxy)ethoxy]acetyl]amino]methyl]-1,2,4,5-tetrazin-3-yl]methylamino]-2-oxoethoxy]ethoxy]acetic acid
2-[2-[2-[[6-[[[2-[2-(Carboxymethoxy)ethoxy]acetyl]amino]methyl]-1,2,4,5-tetrazin-3-yl]methylamino]-2-oxoethoxy]ethoxy]acetic acid化学式
CAS
——
化学式
C16H24N6O10
mdl
——
分子量
460.4
InChiKey
BMGAMYNXDXKUBJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -4.4
  • 重原子数:
    32
  • 可旋转键数:
    18
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    221
  • 氢给体数:
    4
  • 氢受体数:
    14

文献信息

  • [EN] CHANNEL PROTEIN ACTIVATABLE LIPOSOMES<br/>[FR] LIPOSOMES ACTIVABLES PAR DES PROTÉINES DE CANAL
    申请人:TAGWORKS PHARMACEUTICALS B V
    公开号:WO2014081300A1
    公开(公告)日:2014-05-30
    Disclosed is a liposome, comprising a lipid bilayer enclosing a cavity, wherein the bilayer comprises a channel protein releasably linked to an eight-membered non-aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The liposomes are used in a kit comprising the liposome, the liposomal membrane of which comprises a channel protein linked to a Trigger, and an Activator for the Trigger, wherein the Trigger comprises the eight- membered non-aromatic cyclic alkenylene group, and the Activator comprises a diene.
    揭示了一种脂质体,包括包裹腔的脂质双层,其中双层包括与八元非芳香环烯链基(优选为环辛烯基,更优选为反式环辛烯基)可释放地连接的通道蛋白。这些脂质体用于一种套装,包括该脂质体,其脂质体膜包括连接到触发器的通道蛋白,以及用于触发器的激活剂,其中触发器包括八元非芳香环烯链基,而激活剂包括二烯。
  • [EN] ACTIVATABLE LIPOSOMES<br/>[FR] LIPOSOME POUVANT ÊTRE ACTIF
    申请人:TAGWORKS PHARMACEUTICALS B V
    公开号:WO2014081299A1
    公开(公告)日:2014-05-30
    Disclosed are reactive liposome, comprising a lipid bilayer enclosing a cavity, wherein the bilayer comprises a linkage to an eight-membered non-aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The liposomes are use in a kit comprising the liposome linked, directly or indirectly, to a Trigger, and an Activator for the Trigger, wherein the Trigger comprises an eight-membered non-aromatic cyclic alkenylene group, and the Activator comprises a diene.
    揭示了一种反应性脂质体,包括一个脂质双层包裹的腔隙,其中该双层包括与一个含有八个成员的非芳香环烯基基团连接的连接,最好是环辛烯基团,更好是反式环辛烯基团。这些脂质体用于一种工具包,该工具包包括直接或间接地与一个触发器连接的脂质体,以及用于触发器的活化剂,其中触发器包括一个含有八个成员的非芳香环烯基基团,而活化剂包括一个二烯。
  • [EN] BIO-ORTHOGONAL DRUG ACTIVATION<br/>[FR] ACTIVATION DE MÉDICAMENT BIO-ORTHOGONALE
    申请人:TAGWORKS PHARMACEUTICALS B V
    公开号:WO2014081301A1
    公开(公告)日:2014-05-30
    Disclosed is a kit for the administration and activation of a Prodrug. The kit comprises a Masking Moiety linked, directly or indirectly, to a Trigger moiety, which in turn is linked to a Drug, and an Activator for the Trigger moiety. The Trigger moiety comprises a dienophile and the Activator comprises a diene, whereby the dienophile is an eight-membered non- aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The Trigger and the Activator undergo a fast, bio-orthogonal reaction resulting in the release of the Masking Moiety, and activation of the drug.
    揭示了一种用于给予和激活前药的工具包。该工具包包括一个掩蔽基团,直接或间接地连接到一个触发基团,该触发基团又连接到一种药物,以及一个用于触发基团的激活剂。触发基团包括一个二烯烃,激活剂包括一个二烯,其中二烯烃是一个八元非芳香环烯基团,优选为环辛烯基团,更优选为反式环辛烯基团。触发基团和激活剂经历一个快速的生物正交反应,导致掩蔽基团的释放和药物的激活。
查看更多

同类化合物

酸四嗪 甲四嗪-氨基叔丁酯 四嗪-活性脂 四嗪-氨基叔丁酯 嘧啶并[4,5-e]-1,2,3,4-四嗪 二甲基-1,2,4,5-四嗪 二氯均四嗪 METHYLTETRAZINE-ACID,甲基四嗪-羧基 6-苯基-1,2,4,5-四嗪-3-胺 6-乙基-1,2,4,5-四嗪-3-胺 6-丁基氨基-3-(3,5-二甲基吡唑-1-基)四嗪 6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-胺 3-苯基-6-(吡啶-2-基)-1,2,4,5-四嗪 3,6-二苯基-1,2,4,5-四嗪 3,6-二溴-1,2,4,5-四嗪 3,6-二氨基-1,2-二氢-1,2,4,5-四嗪盐酸盐 3,6-二-4-吡啶基-1,2,4,5-四嗪 3,6-二-2-吡啶基-1,2,4,5-四嗪 3,6-二(噻吩-2-基)-1,2,4,5-四嗪 3,6-二(3-吡啶基)-1,2,4,5-四氮杂苯 3,6-二(3,5-二甲基-1H-吡唑-1-基)-1,2,4,5-四嗪 1-[6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-基]-2-(丙-2-亚基)肼 1,2-二氢-1,2,4,5-四嗪-3,6-二酮 1,2,5-噁二唑-3-胺,4-[(5-甲基-2H-四唑-2-基)甲基]- 1,2,4,5]四嗪-3,6-二羧酸 1,2,4,5-四嗪-3-胺 1,2,4,5-四嗪-3,6-二羧酸二甲酯 1,2,4,5-四嗪,3-甲氧基-6-苯基- 1,2,4,5-四嗪 (9CI)-吡咯并[2,1-d]-1,2,3,5-四嗪 (6-肼基-1,2,4,5-四嗪-3-基)肼 3,6-Dicyclopropyl-s-tetrazin 3-Methyl-4-methylaminotriazol-1-oxid 1,2,4,5-Tetrazin-3-amine, 6-cyclohexyl- 7-amino-2-trifluoromethyl-6-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)-4,4a,5,6-tetra-hydroimidazo[1,5-d][1,3,4]thiadiazin-6-ium pentaiodide 3,6-bis(ethylamino)-1,2,4,5-tetrazine Gtersunqcxeonk-uhfffaoysa- aminotetrazine argon 3-amino-s-tetrazine*Ar2 N-(2-chloro-1-methoxyethyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-amine 3,6-di(2-cyclopentylidenehydrazino)-1,2,4,5-tetrazine 4,4'-(butane-2,3-diylidenebis(azaneylylidene))bis(4H-1,2,4-triazole-3-thiol) 6-Isopropyl-s-triazolo<4,3-b>-s-tetrazin-3-thiol 3-amino-6-(3,5-diamino-1,2,4-triazol-1-yl)-1,2,4,5-tetrazine 3,6-bis(4-bromo-3,5-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine 1,4-s-Tetrazin-15N2 N-(sec-butyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-amine 1,2-Di-4-pyridazinylethanone oxime trans-Pt(S[CN4(C2H5)])2(PMe3)2